- Home
- MIRA vs IPA Comparison
MIRA vs IPA Comparison
Compare MIRA & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- IPA
- Stock Information
- Founded
- MIRA 2020
- IPA 1983
- Country
- MIRA United States
- IPA United States
- Employees
- MIRA N/A
- IPA N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- IPA Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- IPA Health Care
- Exchange
- MIRA Nasdaq
- IPA Nasdaq
- Market Cap
- MIRA 19.5M
- IPA 22.4M
- IPO Year
- MIRA 2023
- IPA 2017
- Fundamental
- Price
- MIRA $1.40
- IPA $0.67
- Analyst Decision
- MIRA Strong Buy
- IPA Strong Buy
- Analyst Count
- MIRA 2
- IPA 2
- Target Price
- MIRA $14.00
- IPA $4.00
- AVG Volume (30 Days)
- MIRA 265.8K
- IPA 541.9K
- Earning Date
- MIRA 05-14-2025
- IPA 07-28-2025
- Dividend Yield
- MIRA N/A
- IPA N/A
- EPS Growth
- MIRA N/A
- IPA N/A
- EPS
- MIRA N/A
- IPA N/A
- Revenue
- MIRA N/A
- IPA $16,581,105.00
- Revenue This Year
- MIRA N/A
- IPA $4.67
- Revenue Next Year
- MIRA N/A
- IPA $14.15
- P/E Ratio
- MIRA N/A
- IPA N/A
- Revenue Growth
- MIRA N/A
- IPA 1.34
- 52 Week Low
- MIRA $0.51
- IPA $0.27
- 52 Week High
- MIRA $5.01
- IPA $1.08
- Technical
- Relative Strength Index (RSI)
- MIRA 62.38
- IPA 73.71
- Support Level
- MIRA $1.29
- IPA $0.50
- Resistance Level
- MIRA $1.44
- IPA $0.75
- Average True Range (ATR)
- MIRA 0.10
- IPA 0.05
- MACD
- MIRA 0.00
- IPA 0.01
- Stochastic Oscillator
- MIRA 85.81
- IPA 72.68
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.